These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1998 related items for PubMed ID: 7025339

  • 1. Comparison of the relative fibrinogenolytic, fibrinolytic and thrombolytic properties of tissue plasminogen activator and urokinase in vitro.
    Matsuo O, Rijken DC, Collen D.
    Thromb Haemost; 1981 Jun 30; 45(3):225-9. PubMed ID: 7025339
    [Abstract] [Full Text] [Related]

  • 2. Studies on the specific fibrinolytic effect of human extrinsic (tissue-type) plasminogen activator in human blood and in various animal species in vitro.
    Korninger C, Collen D.
    Thromb Haemost; 1981 Aug 28; 46(2):561-5. PubMed ID: 6795744
    [Abstract] [Full Text] [Related]

  • 3. In vitro studies on the fibrinolytic, thrombolytic and fibrinogenolytic properties of a tissue plasminogen activator from guinea pig keratocytes.
    Electricwala A, Ling RJ, Sutton PM, Griffiths B, Riley PA, Atkinson T.
    Thromb Haemost; 1985 Apr 22; 53(2):200-3. PubMed ID: 4040659
    [Abstract] [Full Text] [Related]

  • 4. Absence of synergism between tissue-type plasminogen activator (t-PA), single-chain urokinase-type plasminogen activator (scu-PA) and urokinase on clot lysis in a plasma milieu in vitro.
    Collen D, De Cock F, Demarsin E, Lijnen HR, Stump DC.
    Thromb Haemost; 1986 Aug 20; 56(1):35-9. PubMed ID: 3095946
    [Abstract] [Full Text] [Related]

  • 5. Biological and thrombolytic properties of proenzyme and active forms of human urokinase--IV. Variability in fibrinolytic response of plasma of several mammalian species.
    Lijnen HR, De Wreede K, Demarsin E, Collen D.
    Thromb Haemost; 1984 Aug 31; 52(1):31-3. PubMed ID: 6495261
    [Abstract] [Full Text] [Related]

  • 6. Biological and thrombolytic properties of proenzyme and active forms of human urokinase--I. Fibrinolytic and fibrinogenolytic properties in human plasma in vitro of urokinases obtained from human urine or by recombinant DNA technology.
    Zamarron C, Lijnen HR, Van Hoef B, Collen D.
    Thromb Haemost; 1984 Aug 31; 52(1):19-23. PubMed ID: 6495259
    [Abstract] [Full Text] [Related]

  • 7. Thrombolytic and pharmacokinetic properties of a recombinant chimeric plasminogen activator consisting of a fibrin fragment D-dimer specific humanized monoclonal antibody and a truncated single-chain urokinase.
    Dewerchin M, Vandamme AM, Holvoet P, De Cock F, Lemmens G, Lijnen HR, Stassen JM, Collen D.
    Thromb Haemost; 1992 Aug 03; 68(2):170-9. PubMed ID: 1412163
    [Abstract] [Full Text] [Related]

  • 8. Selective fibrinolytic activity of recombinant non-glycosylated human pro-urokinase (single-chain urokinase-type plasminogen activator) from bacteria.
    Hanbücken FW, Schneider J, Günzler WA, Friderichs E, Giertz H, Flohé L.
    Arzneimittelforschung; 1987 Aug 03; 37(8):993-7. PubMed ID: 3118890
    [Abstract] [Full Text] [Related]

  • 9. Biological properties of human tissue-type plasminogen activator obtained by expression of recombinant DNA in mammalian cells.
    Collen D, Stassen JM, Marafino BJ, Builder S, De Cock F, Ogez J, Tajiri D, Pennica D, Bennett WF, Salwa J.
    J Pharmacol Exp Ther; 1984 Oct 03; 231(1):146-52. PubMed ID: 6541693
    [Abstract] [Full Text] [Related]

  • 10. Effect of standard heparin and a low molecular weight heparin on thrombolytic and fibrinolytic activity of single-chain urokinase plasminogen activator in vitro.
    Lourenço DM, Dosne AM, Kher A, Samama M.
    Thromb Haemost; 1989 Nov 24; 62(3):923-6. PubMed ID: 2556812
    [Abstract] [Full Text] [Related]

  • 11. Effects of pro-urokinase and urokinase on the fibrinolytic system in man.
    Trübestein G, Popov S, Wolf H, Welzel D.
    Haemostasis; 1987 Nov 24; 17(4):238-44. PubMed ID: 2442078
    [Abstract] [Full Text] [Related]

  • 12. Biological and thrombolytic properties of proenzyme and active forms of human urokinase--III. Thrombolytic properties of natural and recombinant urokinase in rabbits with experimental jugular vein thrombosis.
    Collen D, Stassen JM, Blaber M, Winkler M, Verstraete M.
    Thromb Haemost; 1984 Aug 31; 52(1):27-30. PubMed ID: 6541817
    [Abstract] [Full Text] [Related]

  • 13. Potentiation by Lys-plasminogen of clot lysis by single or two chain urokinase-type plasminogen activator or tissue-type plasminogen activator.
    Watahiki Y, Scully MF, Ellis V, Kakkar VV.
    Thromb Haemost; 1989 Jun 30; 61(3):502-6. PubMed ID: 2508259
    [Abstract] [Full Text] [Related]

  • 14. Fibrin clot lysis by thrombolytic agents is impaired in newborns due to a low plasminogen concentration.
    Andrew M, Brooker L, Leaker M, Paes B, Weitz J.
    Thromb Haemost; 1992 Sep 07; 68(3):325-30. PubMed ID: 1440499
    [Abstract] [Full Text] [Related]

  • 15. Vampire bat salivary plasminogen activator promotes robust lysis of plasma clots in a plasma milieu without causing fluid phase plasminogen activation.
    Hare TR, Gardell SJ.
    Thromb Haemost; 1992 Aug 03; 68(2):165-9. PubMed ID: 1412162
    [Abstract] [Full Text] [Related]

  • 16. [Changes in the components of the animal fibrinolytic system induced by the action of physiological activators and enzymes of fungal origin].
    Andreenko GV, Serebriakova TN, Shimonaeva EE, Liutova LV, Karabasova MA.
    Nauchnye Doki Vyss Shkoly Biol Nauki; 1983 Aug 03; (3):51-4. PubMed ID: 6342687
    [Abstract] [Full Text] [Related]

  • 17. Coronary thrombolysis with tissue-type plasminogen activator in patients with evolving myocardial infarction.
    Van de Werf F, Ludbrook PA, Bergmann SR, Tiefenbrunn AJ, Fox KA, de Geest H, Verstraete M, Collen D, Sobel BE.
    N Engl J Med; 1984 Mar 08; 310(10):609-13. PubMed ID: 6537987
    [Abstract] [Full Text] [Related]

  • 18. [An experimental study of local fibrinolysis using tissue plasminogen activator and urokinase in a canine common carotid artery thrombus model].
    Kawakami K, Takahashi A, Yoshimoto T.
    No To Shinkei; 1990 Feb 08; 42(2):193-201. PubMed ID: 2113401
    [Abstract] [Full Text] [Related]

  • 19. Systemic fibrinolytic activity and inhibitor levels during treatment of deep vein thrombosis with urokinase and streptokinase.
    Theiss W, Asbeck F, Kriessmann A, Trübestein G, Knoch K, de Swart CA, Marbert GA, van de Loo JC.
    Thromb Haemost; 1983 Oct 31; 50(3):664-8. PubMed ID: 6196852
    [Abstract] [Full Text] [Related]

  • 20. Thrombolysis with human extrinsic (tissue-type) plasminogen activator in rabbits with experimental jugular vein thrombosis. Effect of molecular form and dose of activator, age of the thrombus, and route of administration.
    Collen D, Stassen JM, Verstraete M.
    J Clin Invest; 1983 Feb 31; 71(2):368-76. PubMed ID: 6681615
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 100.